CogState Aktie

CogState EBITDA-margin

Delisted·15. jun. 2026

EBITDA-margin for CogState (CGS.AX) pr. 8. aug. 2026 er 29,59 %. I foregående år var EBITDA-margin 21,90 % — en ændring på 35,13 % (højere).

EBITDA-margin

29,59 %

YoY

35,13%

Senest opdateret:

EBITDA-margin for CogState er 2026 29,59 % . EBITDA-margin for CogState var 2025 21,90 % . Det falder dermed med 35,13% højere sammenlignet med året før.
Access this data via the Eulerpool API

CogState Aktieanalyse

Hvad laver CogState? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om CogState aktie

EBITDA-margin for CogState er 29,59 % i 2026.

EBITDA-margin for CogState ændrede sig fra 21,90 % til 29,59 %, hvilket repræsenterer en ændring på 35,13 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA-margin CogState siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA-marginen viser, hvilken procentdel af omsætningen der konverteres til EBITDA. Den normaliserer for af- og nedskrivninger og kapitalstrukturforskelle.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne EBITDA-margins CogState med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere EBITDA-margins er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for EBITDA-margin.

Access this data via the Eulerpool API

Marginer — CogState

Alle nøgletal — CogState